News & Publications

Please save the date to join us for our annual 2022 Merkel CELLebration/ Dinner on Monday, September 12th beginning at 3pm (PDT). This year we will have a hybrid event with an option to join a livestreamed presentation from 5-6 pm (PDT), followed by a dinner reception. The in-person events will be h...

Several faculty, trainees and researchers representing UW Dermatology presented their research at the SID Annual Meeting in Portland, Oregon from May 18-21, 2022. Each year, the Society for Investigative Dermatology (SID)’s Annual Meeting invites a diverse group of researchers and clinicians, as w...

The UW Division of Dermatology hosted the 2nd International Symposium on Merkel Cell Carcinoma in Seattle, WA, from April 25-26, 2022. The two-day hybrid (in-person and virtual) event held at the Graduate Hotel brought together over 140 thought leaders, active investigators, faculty and trainees in ...

The 16th Annual MCC Multi-center Interest Group (MMIG) Meeting took place on March 25, 2022 at the American Academy of Dermatology Annual Meeting in Boston, MA. Here we summarize talks given by Lisa Zaba, MD, PhD, Lindsay Gunnell, MD, Sophia Shalhout, PhD, Mackenzie Martin, BA, Anna Szumera-Cieckiew...

Congratulations to several members of the Nghiem Lab Research Team whose recent proposal was selected to receive over $1.2 million in award funding through The Mark Foundation to support their innovative Merkel cell carcinoma (MCC) research. The research team includes Peter Goff, MD, PhD, Senior...

Congratulations to UW Dermatology’s Nghiem Lab Research Team, and partners from around the world, who have recently been awarded a $4 million grant from Innovation Fund Denmark (IFD) to develop and clinically test the ImmPACT cell product in Merkel cell carcinoma. The project will explore the po...

MCC made it into the NY Times in the form of this fascinating medical mystery story. A ‘paraneoplastic syndrome’ is when a tumor causes a process to happen in the body indirectly, such as via an immune response to the tumor that attacks another part of the body (as happened here) or because the ...

The first-ever therapeutic vaccine trial for Merkel cell carcinoma is set to start in April 2022, based in Seattle. This will be a small trial in only eight patients to initially check safety and whether the immune response targeting the Merkel cell polyomavirus is indeed increased in these patients...

Dr. Mac Cheever was a true pioneer in immune therapy for cancer. His efforts have helped many patients with cancer, but particularly those with Merkel cell carcinoma, helping to lead to the approval of anti-PD1 for MCC. This tribute to his life details why he believed that immune therapy for cancer ...

Dear friends of Merkel cell carcinoma research,   Greetings! I hope that you are having a wonderful start to the holiday season. Your partnership is vital to accelerating discoveries that will continue to unlock better outcomes for patients and their families, today and for years to come. I...